newsfilter
← Latest News
GlobeNewswire·

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

IMDX
  • Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) appointed Donnie Purto as Senior Vice President of Sales to lead commercialization efforts for GraftAssureDx.
  • GraftAssureDx is currently under FDA review & awaits regulatory authorization for clinical use.
  • Purto brings over 20 years of experience in diagnostics & healthcare, including a decade at Natera, Inc. managing significant revenue & new product launches.
  • CEO Josh Riggs stated the company aims to disrupt transplanted organ health testing in 2027 with Purto leading the initiative.
  • Purto noted existing strong relationships with high-volume kidney transplant centers like Cleveland Clinic, Mayo Clinic, & Vanderbilt University that supported the FDA submission.
  • iMDx utilizes donor-derived cell-free DNA (dd-cfDNA) as a biomarker for transplant rejection monitoring.
  • The company's transplant portfolio includes GraftAssureCore (reimbursed LDT), GraftAssureIQ (RUO kit), & GraftAssureDx (pending IVD kit).
  • GraftAssureCore is performed at iMDx's CLIA-certified laboratory in Franklin, Tennessee.
  • The press release includes standard forward-looking statements regarding expected FDA authorization, commercial launch, & future product development.